MarkFKozloffMD

Oncology • Harvey, IL

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Clinical Associate Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Kozloff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kozloff's full profile

Already have an account?

Office
71 W 156th St
Suite 401
Harvey, IL 60426
Phone+1 708-339-4800

Fax+1 708-339-3760

Summary

Dr. Mark Kozloff is an oncologist in Chicago, IL and is affiliated with multiple hospitals in the area, including University of Chicago Medical Center and Ingalls Memorial Hospital. He received his medical degree from University of Michigan Medical School and has been in practice 45 years. He specializes in gastrointestinal cancer, hematologic oncology, and thoracic cancer and is experienced in hodgkin's lymphoma.

Education & Training

University of MichiganResidency, Internal Medicine, 1975 - 1977
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1972 - 1975
University of Michigan Medical SchoolClass of 1972
University of MichiganB.S., 1966 - 1968
Michigan State UniversityA.D., 1964 - 1966

Certifications & Licensure

MI State Medical License Current
IL State Medical License 1973 - 2026
IN State Medical License 1989 - 2015
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Clinical Trials Participation Award Conquer Cancer Foundation of the American Society of Clinical Oncology, 2014
Hematology/ Oncology Fellowship, Medicine Education Award University of Chicago, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer Start of enrollment: 2006 Jul 01
Unknown status
Not Applicable
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Start of enrollment: 2008 Jun 01
Completed
Phase 1
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
Completed
Phase 1, Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15
Active, not recruiting
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer Start of enrollment: 2020 Jun 17
Recruiting
Phase 2, Phase 3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
A Study of miRNA 371 in Patients With Germ Cell Tumors Start of enrollment: 2020 Jul 28
Recruiting
Join now to see all

Publications & Presentations

PubMed

385 citations
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba
Journal of Clinical Oncology. 2015-12-20
7 citations
Zinc abuse and sideroblastic anemia.
Jayanthi Ramadurai, Charles Shapiro, Mark Kozloff, Margaret Telfer
American Journal of Hematology. 1993-02-01
38 citations
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace
The Oncologist. 2017-03-01

Journal Articles

Primary Systemic therapy in resectable pancreatic ductal adenocarcinoma using Mfolfirinox: A pilot study
Robert de W, Marsh MD, Mark S. Talamonti MD, Marshal S. Baker MD, Mitchell Posner MD, Kevin Roggin MD, Jeffrey Matthews MD, Daniel Catenacci MD, Mark Kozloff MD, Blasé..., Journal of Surgical Oncology, 1/16/2017
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
Rangwala F. Bendell JC, Kozlof MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uron..., Investigational New Drugs, 1/9/2014
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin Registry - Investigation of Effectiveness and Safety...
Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, Clinical Oncology, 1/1/2014
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumors
MF Kozloff, LP Martin, M Krazkowski, TA Samuel, TA Rado, E Arriola, J De Castro Carpeno, RS Herbst, J Tarazi, S Kim, B Rosbrook, M Tortoricil, AJ Olszanskil and RB Cohen, British Journal of Cancer, 1/1/2012
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
LP Martin, MF Kozloff, RS Herbst, TA Samuel, S Kim, B Rosbrook, M Tortorici, Y Chen, J Tarazi, AJ Olszanski, T Rado, A Starr and RB Cohen, British Journal of Cancer, 1/1/2012
Sunitinib in Combination with Docetaxel and Predinisone in Chemotherapy-Naïve Patients with Metastatic, Castration-Resistant Prostate Cancer: A Phase 1/2 Clinical Trial
Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen L, Chow Maneval E, Logothetsis CJ, Annals of Oncology, 1/1/2011
Personalized Colon Cancer Care in 2010
Catenacci DVT, Kozloff M, Kindler HL and Polite B, Seminars in Oncology, 1/1/2011
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumag and Chemotherapy: Results from the BRiTE Observational Cohort Study
Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A, for the BRiTE Investigators, Oncology: International Journal of Cancer Research and Treatment, 1/1/2010
An Exploratory Study of Sunitinib Plus Paclitaxel as First-Line Treatment for Patients with Advanced Breast Cancer
Kozloff MF, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, and Miller K, Annals of Oncology, 1/1/2010
Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma
Choong NW, Kozloff MF, Taber D, Hu HS, Wade III J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE, Springer Science + Business Media LLC, 1/4/2009
Clinical Outcomes Associates with Bevacuzumab-Containing Treatment of Metastatic Colorectal Cohort Study: The BRiTE Observational Cohort Study
Kozloff MF, Ulcickas Yood, M., Belin, J, Flynn, P.J., Kabbinavar, F.F., Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Oncologist, 1/2/2009
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cander: the BRiTE observational cohort study
Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Gothey A, Oncologist, 1/1/2009
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE, Lancet Oncology, 1/1/2009
Cutaneous Eruption Related to Human Epidermal Growth Factor Receptor Inhibitors in Stage IV Colon Cancer
Guzman L, Kozloff MF, Wallace JA, Starr A, Clinical Journal of Oncology Nursing, 1/1/2009
Phase I Study of Axitinib (AG-013736) in Combination with Chemotherapy in Patients (Pts) with Advanced Solid Tumours
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Tarazi J, Olszanski AJ, Cohen RB, Annals of Oncology, 1/8/2008
Phase I Trial of Erlotinib-Based Multimodality Therapy for inoperable Stage III Non-Small Cell Lung Cancer
Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff MF, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE, Journal of Thoracic Oncology, 1/1/2008
A Phase II Study of ABT-751 in Patients with Advanced Non-Small Cell Lung Cancer
Mauer AM, Cohen EW, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB, Journal of Thoracic Oncology, 1/1/2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BR...
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M, Journal of Clinical Oncology, 1/1/2008
Safety Outcomes Associated with Long-Term, Continuous Exposure to Bevacizumab (BC) and Chemotherapy (CT) in Patients (Pts) with MCRC: Results from the BRiTE Observatio...
Kozloff MF, Berlin J, Flynn PJ, Grothey A, Kabbinavar F, Sargent D, Dong W, Purdie D, Sugrue M, Annals of Oncology, 1/1/2008
Phase II Study of Mitoxantrone and Ketoconazole for Hormone Refractory Prostate Cancer
Eklund, John, Kozloff, MF, Vlamakis, Joy, Starr, Alexander, Mariott, Margaret, Gallot, Lilia, Jovanovic Borko, Schilder, Lawrence, Robin, Erwin, Pins, Michael, Bergan..., Wiley InterScience, 1/13/2006
Phase II Trial of temozolomide and Irinotecan as second-line treatment for advanced non-small cell lung cancer
Choong N, Mauer A, Hoffman P, Rudin C, Winegarden III J, Villano J, Kozloff MF, Wade III J, Sciortino D, Szeto L, Vokes EE, Journal of Thoracic Oncology, 1/1/2006
Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined with Carboplatin and Etoposide in Patients with Small-Cell Lung Canacer
Rudin CM, Kozloff MF, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE, J Clin Oncol, 1/15/2004
Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head...
Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, and Vokes EE, Clinical Cancer Research, 1/1/2004
Induction Chemotherapy Followed by Concurrent Chemoradiation for Advanced Head and Neck Cancer Improved Disease Control and Survival
Kies M, Haraf D, Athanasadis Z, Kozloff MF, Mittal B, Pelzea H, Rademaker A, Wenig B, Weichselbaum RR, and Vokes EE, J Clin Oncol, 1/1/1998
Mononeuropathy Multiplex Due to Infiltration of Lymphoma in Hematologic Remission
Walk D, Handelsman A, Beckmann E, Kozloff MF, Shapiro C, Muscle Nerve, 1/1/1998
Join now to see all

Books/Book Chapters

Neo-adjuvant Chemotherapy.
Chapter: Cisplatin, 5-fluorouracil and high dose oral ceucovorin (PFL) with nethotrexate and piritrexim as neoadjuvant chemotheraphy for head and neck cancer.
Page 58 - 60Vokes EE, Haraf DJ, Panje WR, McEvilly JM, Kozloff MF, Goldman MD, Clendeninn N, Tybor AF, Collier M, Weischselbaum RREditors: Banzet P, Holland JF, Khayat D, Weil M.Springer-Verlag, Paris, France1991

Abstracts/Posters

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectoal Cancer.
Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, et al, Oncologist, 1/1/2017
Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Ly...
Stephen Stilgenbauer, Franck Marschhasuer, …Mark F. Kozloff, et al, 58th ASH, San Diego, CA, 1/3/2016
Real-world clinical experience in the Connect (R) chronic lymphocytic leukemia registry: a prospective cohort study of 1494 patients across 199 US centres.
Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL Flinn IW, Kozloff MF, et al, British Journal of Haematology, 1/1/2016
Per-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study.
Robert de Wilton Marsh, Marshall Baker, Daniel VT Catenacci, Mark Kozloff, et al, ASCO Gastrointestinal Cancers Symposium, 1/1/2016
Characteristics of Long-Vs Short-Survivng Patients: An Analysis of the ARIES Observational Cohort Study of Bevacizumab-Treated Patients with Metastatic Colorectal Cancer.
Kozloff M, Grothey A, Bendell J, Cohn A, Bekaii-Saab T, Roach N, Mun Y, Fish S, Laeufle R, Sommer N, and Hurwitz H, Gastrointestinal Cancers Symposium, 1/15/2015
Survival outcomes according to body mass index: Results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer.
Zafar Y, Kozloff M, Hubbard J, Cutsem E, Van Hermann, F, Sorm AJ, Gomez E, Revil C, Grothey A, 17th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 1/1/2015
Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratificatio...
Anthony Mato, Chadi Nabhan…MarkKozloff, et al, Blood; 57th Annual ASH, Orlando, FL, 1/1/2015
Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL (R) Registry.
Charles M. Farber…Mark Kozloff, et al, Blood; 57th Annual ASH, Orlando, FL, 1/1/2015
Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connec CLL (R) C...
Christopher Flowers…Mark Kozloff, Kristen Sullivan, et al, Blood; 57th Annual ASH, Orlando, FL, 1/1/2015
Updated Safety and Prliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refrac...
Gilles A. Salles…Mark Kozloff, Guillame Carton, et al, Blood; 57th Annual ASH, Orlando, FL, 1/1/2015
A Dose-Escalation Study of Ventoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.
Sven de Vos, Lode Swinnen, Mark Kozloff, et al, Blood; 57th Annual ASH, Orlando, FL, 1/1/2015
A dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients with relapsed/refractory (R/R) Non-Hod...
Sven de Vos, Christopher Flowers, Ding Wang, Lode Swinnen, Nathan Fowler, Erin Reid, Jaclyn Cordero, Maryella Gifford, Diane D'Amico, Martin Dunbar, Ming Zhu, Ahmed Sa..., European Hematology Association, Vienna, Austria, 1/1/2015
Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.
Anthony Mato, Christopher Flowers, Charles Michael Farber, Mark Adam Weiss, Thomas J. Kipps, Mark Kozloff…Jef Porter Sharman, ASCO Annual Meeting, 1/1/2015
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relaps...
Swen De Vos, Christopher Flowers, Ding Wang…Mark Kozloff, ASCO Annual Meeting, 1/1/2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibito, in Patients with Metastatic Pancreatic Cancer.
Daniel VT Catenacci, Melissa R. Junttila,…Mark Kozloff, et al, Journal of Clinical Oncology, 1/1/2015
Demographics by Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices from the Connect CLL Registry.
Sharman JP, Mato A, Kay N, Kipps T, Lamanna N, Weiss M, Nabhan C, Flinn I, Grinblatt D, Kozloff MF, Farber C, Sullivan K, Street T, Swern A, and Flowers C, ASH, 1/6/2014
A Randomized, Double-Blinded, Placebo-Controlled Phased II Trial of Gemcitabine Plus Nab-Paclitaxel Combined with OGX-427 (Apatorsen) or Placebo in Patients with Metas...
Bendell JC, Peyton JD, Sommers S, Xiong H, Crane E, Harwin W, Kozloff M, Shipley D, Thompson D, Womack M, Jones SF, Ko AH, ASCO Annual Meeting, 1/1/2014
The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.
De Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Gifford M, D'Amico D, Dunbar M, Zhu M, Yang J, Heitner-Enschede S, Ricker J, Chien D, Humerickhouse R, and Ko..., ASH, 1/1/2014
Overall Survival According to Patient Subgroups: Results from a Pooled Analysis of 5 Observational or Phase IV Studies of Bevacizumab in Metastatic Colorectal Cancer.
Grothey A, Arnold D, Van Cutsem E, Bekaii-Saab TS, Kozloff M, Bennouna J, Revil C, Donica M, Sommer N, Leutgeb B, Ekstrand-Olsen M, Hermann F, Hurwitz H, ESMO, 1/1/2014
Pharmacokinetic (PK) analysis of coadministration of axitinib and pemetrexed/cisplatin (pem/cis) in patients with non-small cell lung cancer (NSCLC).
Totorici MA, Iglesias L, Kozloff MF, Pithavala YK, Ingrosso A, Belani CP, 113th Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, 1/14/2012
Phase Ib Study of Dulanermin Combined with FOLFIRI (+/- Bevacizumab) in Previously Treated Patients with Metastatic Colorectal Cancer.
Kasubhai SM, Bendell JC, Kozloff M, Kapp AV, Ashkenazi A. Royer-Joo S, Portera CC, ASCO Annual Meeting, Chicago, IL, 1/1/2012
Phase Ib Study of Dulanermin Combined with First-line FOLFOX plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Kozloff M, Messersmith WA, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Wainberg ZA, ASCO Annual Meeting, Chicago, IL, 1/1/2012
Similarities in Treatment Patterns and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Initially Treated with Folfox/Bevacizumab (BV) or Folfiri/BV: Re...
Bendell J, Bekali-Saab TS, Cohn AL, Hurwitz H, Kozloff M, Tezcan H, Feng S, Flick ED, Sing A, and Grothey A, on behalf of the ARIES Study Investigators, Gastrointestinal Cancers Symposium, 1/20/2011
Dasatinib (D) in Previously Treated Metastatic Colorectal Cancer (mCRC) Patients: A Phase II Trial of the University of Chicago Phase II Consortium.
Sharma M, Wroblewski K, Kozloff M, Modi SS, Sleckman BG, Taber D, Vokes EE, Stadler WM, Polite BN, Kindler HI, J Clin Oncol; Gastrointestinal Cancers Symposium, 1/1/2011
Clinical Outcomes in Bevacizumab (BV)-Treated Patients (pts) with Metastatic Colorectal Cancer (mCRC): Results from ARIES Observational Cohort Study (OCS) and Confirma...
Cohn A, Bekaii-Saab T, Bendell J, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Flick ED, Sing A, Grothey A, American Society of Clinical Oncology Annual Meeting, 1/4/2010
Join now to see all

Lectures

Breast Cancer Staging
1/22/2016
Colorectal Cancer Staging
1/31/2015
Immunotherapy for Cancer
1/7/2015
Can We Cure Chronic Lymphocytic Leukemia and Follicular Lymphoma?
1/4/2015
Melanoma Staging
1/27/2014
Head & Neck Cancer Staging
1/28/2013
Lung Cancer Staging
1/6/2012
Study Design, Data Interpretation and Bias Management of Observational Studies
1/3/2012
ASCO Update
1/1/2012
ASCO Updates
1/8/2011
Staging and Treatment Updates in Colorectal Cancer
1/4/2010
Controlling Angiogenesis to Control Tumor Growth
Lisbon, Portugal - 1/11/2009
Breast Cancer: The Most Common Malignancy in Females
Matteson, IL - 1/25/2008
ASCO GI Updates
1/20/2007
Colorectal and Breast Cancer Studies
1/2/2007
Emerging Trends in the Management of Colorectal Cancer
1/17/2006
Kidney Cancer Review
1/6/2006
Join now to see all

Press Mentions

Ingalls Advancing Colorectal Cancer Treatment Through ResearchFebruary 28th, 2017